Cargando…

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount of clinical data across diverse patient populations. Despite the fact that olan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Citrome, Leslie, McEvoy, Joseph P, Todtenkopf, Mark S, McDonnell, David, Weiden, Peter J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733343/ https://www.ncbi.nlm.nih.gov/pubmed/31564881 http://dx.doi.org/10.2147/NDT.S209284

Ejemplares similares

Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
por: Correll, Christoph U, et al.
Publicado: (2023)

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
por: Citrome, Leslie, et al.
Publicado: (2021)

Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
por: Todtenkopf, Mark S., et al.
Publicado: (2023)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
por: McDonnell, David P., et al.
Publicado: (2014)

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
por: Hill, Angela L, et al.
Publicado: (2011)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Commentary: Intercultural Competence Past, Present, and Future: Respecting the Past, Problems in the Present, and Forging the Future
por: Bo, Mengmeng, et al.
Publicado: (2022)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome, Leslie, et al.
Publicado: (2019)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
por: Anand, Ernie, et al.
Publicado: (2015)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)

S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER
por: Simmons, Adam, et al.
Publicado: (2018)

Blood Pressure Variability in Clinical Practice: Past, Present and the Future
por: Sheikh, Abu Baker, et al.
Publicado: (2023)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
por: Detke, Holland C, et al.
Publicado: (2010)

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
por: Sun, Lei, et al.
Publicado: (2018)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
por: McEvoy, Joseph P., et al.
Publicado: (2021)

Neurological soft signs in schizophrenia – The past, the present and the future
por: Varambally, Shivarama, et al.
Publicado: (2012)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021)

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial
por: Lysaker, Paul H., et al.
Publicado: (2022)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
por: McDonnell, David P, et al.
Publicado: (2010)

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019)

Response: Commentary: Past, present and future of epigenetics applied to livestock breeding
por: González-Recio, Oscar, et al.
Publicado: (2016)

Schizophrenia relapse, patient considerations, and potential role of lurasidone
por: Citrome, Leslie
Publicado: (2016)

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past,  Present and Future
por: Li, Peng, et al.
Publicado: (2016)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
por: Faden, Justin, et al.
Publicado: (2019)

Gases, God and the balance of nature: a commentary on Priestley (1772) ‘Observations on different kinds of air’
por: McEvoy, John G.
Publicado: (2015)

Imaging, past present and future.
por: McIlrath, E. M.
Publicado: (1998)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder
por: Citrome, Leslie
Publicado: (2006)

Commentary: Corneal biomechanical assessment following refractive surgery: Past, present, and future
por: Lalgudi, Vaitheeswaran G
Publicado: (2021)

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment
por: Detke, Holland C., et al.
Publicado: (2014)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Paliperidone: the evidence of its therapeutic value in schizophrenia
por: Kantrowitz, Joshua, et al.
Publicado: (2007)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Citrome, Leslie
Publicado: (2018)

US Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the Future
por: Kovell, Lara C., et al.
Publicado: (2015)

Comparative effectiveness of antipsychotic drugs in schizophrenia
por: Stroup, T. Scott, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_7f986gkn4l0gsknapgm8avh0i2